The majority of adult cats exposed to feline leukemia virus (FeLV) develop a transient viremia, and clearance of the virus is associated with the development of virus-neutralizing antibody and antibody to the feline oncovirus-associated cell membrane antigen (FOCMA) (3, 7, 12, 28) .
These cats are designated as regressors, and many of them have latent infection present in the bone marrow and lymph nodes as demonstrated by the presence of viral antigen in cultured myelomonocytic and lymphoid cells (29) . Prevention of reactivation of FeLV infection in vivo may depend on an intact host immune system, since administration of highdose steroids to regressor cats results in recurrence of viremia (29) .
Although the natural history of FeLV infection and the importance of the immune response in controlling this infection have been intensively studied (4, 8, 13, 14) , all the factors important in containing latent infection have not been established. We hypothesized that the complement system might play a role in containment of latent infection because of the following observations. (i) Addition of FeLV to normal human or cat serum activates the complement system with virolysis secondary to the generation of the C5 through C9 membrane attack complex (16 (2, 15) . (iv) Antibody production against certain antigens and antibody-mediated cytotoxicity may require normal complement activity (17, 20, 21) . (v) An intact complement system has been shown to be important in clearance of other viral infections (10) .
In this study, we evaluated the role of complement in preventing reactivation of FeLV infection by examining the effects of complement depletion on regressor cats with latent infection.
Self-limiting FeLV infection was established in five adult specific-pathogen-free cats by intraperitoneal injection of the Rickard strain of FeLV in an inoculum of a thymic lymphosarcoma homogenate (5, 24 (25, 26, 29) .
Total. hemolytic complement in these cats was determined by a modification of the method of Mayer (22) Complement depletion was achieved by intraperitoneal injection of cobra venom factor (CVF) derived from Naja Haje species (lot no. 74160; Cordis, Miami, Fla.); 200 U/kg were given in four divided doses over 24 h (1).
Before complement depletion, all cats had negative smears for FeLV P27 on blood and bone marrow exams but had evidence of latent viral infection as demonstrated by myelomonocytic cells that were positive for P27 after in vitro culture (29) . Since an increase in immune complex levels has been seen in cats with persistent viremia (2, 34), we next measured immune complex levels after CVF treatment. Three of the five cats showed a significant increase in Clq-precipitable immune complexes within 1 to 3 weeks after treatment. In two of the cats, this correlated with an increase in P27 in the bone marrow or blood. However, in the third cat, immune complexes were elevated without alteration of virus expression (Fig. 1) .
Previous studies have demonstrated that immunosuppressive therapy such as corticosteroids and nitrosoureas significantly impaired host resistance to experimental infection with FeLV (29, 31) and allowed for the reactivation of latent infection in FeLV-immune cats (29) . The host immune mechanisms which appeared to play a significant role in clearing FeLV and preventing reactivation included complement-dependent antibodies to FeLV-infected cells and antibody to virus alone (4, 12, 18, 19, 25) .
In this study, we found that regressor cats made hypocomplementeric by CVF treatment had evidence of increased viral replication in bone marrow myelomonocytic cells and elevated levels of circulating immune complexes, suggesting a role for complement in preventing viral reactivation. Although these cats did not develop the persistent viremia seen when regressor cats were treated with pharmacological doses of steroids, this may be due to the difference in degree and duration of immunosuppression achieved (1, 20, 21, 27 
